Trials / Recruiting
RecruitingNCT06322238
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
A Multi-gene Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice: Open-label, Mayo Clinic Multisite (Mayo Clinic Health System-Rochester Primary Care), Controlled, Implementation Study Taking the Results of the PREPARE Study Into Minnesota (PREPARE-Mayo)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug').
Conditions
- Pharmacogenomic Drug Interaction
- Side Effect of Drug
- Ineffective Drug Action
- Drug Metabolism, Poor, CYP2D6-Related
- Drug Metabolism, Poor, CYP2C19-Related
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | PGx panel test | In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mayo Clinic Health System), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available. |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2026-12-01
- Completion
- 2027-04-01
- First posted
- 2024-03-21
- Last updated
- 2025-10-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06322238. Inclusion in this directory is not an endorsement.